Corrigendum to ‘IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications’: [Annals of Oncology 34 (2023) p693-702, (S0923753423006944), (10.1016/j.annonc.2023.05.009)]

M. Burotto*, Z. Zvirbule, A. Mochalova, Y. Runglodvatana, L. Herraez-Baranda, S. N. Liu, P. Chan, E. Shearer-Kang, X. Liu, N. Tosti, J. A. Zanghi, B. Leutgeb, E. Felip

*Corresponding author for this work

Research output: Contribution to journalComment/debate

Fingerprint

Dive into the research topics of 'Corrigendum to ‘IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications’: [Annals of Oncology 34 (2023) p693-702, (S0923753423006944), (10.1016/j.annonc.2023.05.009)]'. Together they form a unique fingerprint.

Medicine & Life Sciences